Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Octreotide-induced bradycardia

A M Herrington1, K W George, C C Moulds

  • 1Department of Pharmacy Services, Scott & White Memorial Hospital, Texas A&M University Health Science Center, Temple 76508, USA.

Pharmacotherapy
|April 17, 1998
PubMed
Summary

Octreotide can cause serious hemodynamic issues, including bradycardia, even in patients without acromegaly. This drug should be considered a potential cause of bradycardia in clinical practice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effective treatment of lower respiratory tract infections.

PharmacoEconomics·1996
Same author

Toxicology and management of acute drug ingestions in adults.

Pharmacotherapy·1995
Same author

Preventing theophylline dosing errors from conversion of dyphylline.

The Annals of pharmacotherapy·1993
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Octreotide and somatostatin are synthetic analogs used to treat various endocrine and gastrointestinal conditions.
  • Their use is well-documented in acromegaly, but data on other conditions are limited.

Observation:

  • A nonacromegalic patient experienced deleterious hemodynamic effects, specifically bradycardia, while on octreotide therapy for a pancreatic fistula.
  • This adverse event prompted a review of existing literature.

Findings:

  • A MEDLINE search revealed limited data on octreotide-induced complications in patients with conditions other than acromegaly.
  • Bradycardia is a potential, underreported adverse effect of octreotide therapy across different patient populations.

Implications:

  • Clinicians should consider octreotide as a potential cause of bradycardia in patients presenting with this symptom, regardless of their primary diagnosis.
  • Further research is warranted to fully understand the safety profile of octreotide in nonacromegalic patients.

Related Experiment Videos